Think cancer screening tests are confusing? So does your doctor

According to an internet survey conducted by researchers at the Max Planck Institute for Human Development in Berlin among over 400 US primary care physicians, cancer screening tests, and the statistics involved in their outcomes, are not being properly interpreted by doctors, and those doctors are making the wrong recommendations.

The survey presented two hypothetical scenarios and the respondent was required to make one of two recommendations:

-- A cancer screening test based on 5-year survival and earlier detection
-- A cancer screening test that was based on reduced mortality in a randomized trial

Over three-quarters of the respondents made the first recommendation. That is the incorrect one, in part because of the biases to which 5-year survival and earlier detection are subject to, including overdiagnosis.

Only one quarter correctly made the second recommendation, which according to the National Cancer Institute is the only metric that can reliably be considered proof that a certain screening test indeed saves lives.

The authors of the study, which appeared in the Annals of Internal Medicine, noted, "Misunderstanding of statistics ... matters, because it may influence how physicians discuss screening with their patients or how they teach trainees."

Source: MedPage Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap